Kornimate/medical-research-clean huggingface dataset:
early palliative care for patients with haematological malignancies

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Diffuse Large B Cell Lymphoma; Palliative Care

Summary: patients suffering from haematological disease present symptoms of discomfort and currently benefit from palliative care skills only for the management of their end-of-life. however, in medical oncology, more and more studies tend to demonstrate the benefit on the quality of life of an early collaboration between the two specialties. investigator did the hypothesis that early integration of palliative care with conventional haematological care could decrease discomfort symptoms and add a real benefit on the patients' quality of life .

patients suffering from haematological disease present symptoms of discomfort and currently benefit from palliative care skills only for the management of their end-of-life. however, in medical oncology, more and more studies tend to demonstrate the benefit on the quality of life of an early collaboration between the two specialties. investigator did the hypothesis that early integration of palliative care with conventional haematological care could decrease discomfort symptoms and add a real benefit on the patients' quality of life .

Eligibility criteria:
inclusion criteria: * patients are over 70 years old * patients from being diagnosed with acute myeloid leukemia and high-risk myelodysplastic syndrome or after the third line of therapy for high-grade lymphoma. exclusion criteria: * all patients with a curative project (induction chemotherapy ou allogenic transplantation) * all patients in a terminal palliative status * patients who don't speak french, * patients not able to read and write * patients who don't agree to participate in the protocol * patients with psychiatric troubles or cognitive disorders * patients under guardianship or curatorship, deprived of freedom or under justice protection.

Keywords: supportive care early palliative care quality of life symptoms management haematological malignancy
burden of cytomegalovirus reactivation in pediatric patients after allogeneic hematopoietic stem cell transplantation

Conditions: Cytomegalovirus Infection; Hematopoietic Stem Cells Transplantation

Summary: this observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the understanding of cytomegalovirus clinical and economic burden and clinical management of pediatric patients undergoing allogeneic hematopoietic stem cells transplantation in italy.

this is an observational retrospective analysis from the main pediatric centers in italy (approximately 5 sites). the selected sites will be the most representative of italy because they perform about 2/3 of all allogeneic hsct per year. index date: date of allogeneic hsct; retrospective data will be captured in consecutive patients undergoing allogeneic hsct from january 2018 to june 2020 with maximum 12 months of follow-up for each patient. the data of the patients undergoing allogeneic hsct after june 2020 will not be captured in order to avoid any possible bias due to off-label access to letermovir. medical records (mr) will be used to describe the risk factors, patient characteristics, treatment patterns, and healthcare resource utilization of subjects who had a cmv infection. electronic or paper hospital charts (inpatient), clinical charts (inpatient and outpatient), and outpatient records will all be considered as mr for study purposes. this is a secondary data collection study from electronic or paper medical chart review, no data from registry will be collected. patients (or their legally acceptable representatives) must have signed and dated the informed consent \& privacy form (icf), if applicable.

Eligibility criteria:
inclusion criteria: * patients from birth to less than 18 years of age (at the moment of the allogeneic hsct); * patients who received allogeneic hsct between january 2018 and june 2020; * patients (or their legally acceptable representatives) must have signed and dated the informed consent \& privacy form (icf), if applicable. exclusion criteria: * letermovir use at any time
68ga citrate pet/mri for evaluation of fever of unknown origin (fuo)

Conditions: Fever of Unknown Origin

Summary: this is a phase iii study to evaluate 68ga citrate pet/mri for detection of origin of fever of unknown origin.

the purpose of this research study is to evaluate a pet tracer (68ga-citrate) that can localize the origin of patients diagnosed with fever of unknown origin (fuo) using a pet/mri scanner. we hope to learn if this can detect fuo better than with the present nuclear imaging standard of care (67ga spect). we propose the following aim: • to evaluate 68ga citrate pet/mri for detection of origin of fever in patients with fever of unknown origin. patients disgnosed with fever of unknown origin are injected intravenously (iv) with 370 mbq of 68ga citrate. 45-60 minutes later, a whole body pet/mri images are obtained.

Eligibility criteria:
inclusion criteria: * patient is \>/=18 years old at the time of the scan. * patient with diagnosis of fuo. * patient is capable of complying with study procedures. * patient can remain still for duration of imaging procedure. * able to provide written consent. exclusion criteria: * patient is pregnant or nursing. * metallic implants (contraindicated for mri). * history of renal insufficiency (only for mri contrast administration). * inability to lie still for the entire imaging time. * inability to complete the needed investigational and standard of care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.). * any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance. * known allergy, hypersensitivity, or intolerance to the investigational product or its excipients.
multicentric observational study confirming the performance and safety of the axiom® bl x3 implants

Conditions: Surgical Operation; Edentulous Jaw; Edentulous Mouth; Implant

Summary: this post-market clinical follow-up study aims to document the success and survival of the axiom® bl x3 implants up to 3 years after loading.

the total study duration for each patient should be 3 years after loading. . the investigational devices are ce-(conformité européenne, meaning european conformity) marked product. 14 centers will participate in france implants used are axiom® bl x3 with lengths ranging from 6.5 to 18 mm and diameters ranging from 3.4 to 6.4 mm. the study and any amendments will be performed as far as possible according to international organization for standardization (iso) 14155, 21cfr 820 for fda requirement and conform to the declaration of helsinki (last revision fortaleza 2013) and local legal and regulatory requirements.

Eligibility criteria:
inclusion criteria: * patients must provide their informed consent for study participation and must be willing and able to attend control visit (in the standard of care) * patients must be males or females who are a minimum of 18 years of age * patients seeking an implant supported restoration * patient affiliated to (or beneficiary of) the french social security * patients who do not present any contraindication for implant restoration, in accordance to ifu exclusion criteria: * patients who have no follow-up visit planned with the investigator or co-investigators * patients with conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance with study visit or unreliability * a woman who is pregnant or planning to become pregnant at any point during the study duration * patients currently participating in another clinical research * patients who present contraindication for implant restoration, in accordance to ifu * adults under guardianship

Keywords: survival rate success rate anthogyr axiom® bl x3
imatinib mesylate in treating patients with liver metastasis from a gastrointestinal stromal tumor

Conditions: Gastrointestinal Stromal Tumor; Metastatic Cancer

Summary: rationale: imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. purpose: this phase ii trial is studying the side effects of imatinib mesylate and to see how well it works in treating patients with liver metastasis from a gastrointestinal stromal tumor.

objectives: * to evaluate the safety and efficacy of imatinib mesylate in patients with resectable hepatic metastasis secondary to gastrointestinal stromal tumor. outline: this is a multicenter study. patients receive oral imatinib mesylate daily. treatment continues in the absence of disease progression or unacceptable toxicity.

Eligibility criteria:
disease characteristics: * diagnosis of gastrointestinal stromal tumor (gist) * hepatic metastasis meeting the following criteria: * no more than 3 hepatic metastases * clinically diagnosed as surgically resectable with no macroscopic residual tumor * synchronous hepatic metastasis allowed provided primary tumor is also resectable * no metastatic tumor that requires radiofrequency ablation and/or microwave coagulation therapy to control the disease * no extrahepatic metastasis * no history of gist recurrence patient characteristics: * ecog performance status 0-1 * leukocyte count ≥ 3,000/μl * neutrophil count ≥ 1,500/μl * hemoglobin ≥ 8.0 g/dl * platelet count ≥ 75,000/μl * total bilirubin ≤ 2.0 mg/dl * alt and ast \< 120 iu/l * gtp \< 210 iu/l * not pregnant * no poorly controlled diabetes mellitus * no nyha class iii-iv cardiac function * no hepatitis b or hepatitis b carriers * no other malignancy requiring treatment prior concurrent therapy: * see disease characteristics * no prior imatinib mesylate * no prior interventional radiology for metastatic disease * no other concurrent treatment, including surgery or radiotherapy, for metastatic lesions

Keywords: gastrointestinal stromal tumor liver metastases
selenium and ischemic stroke outcome

Conditions: Ischemic Stroke

Summary: selenium is a trace element essential to human health.selenium protection against cellular damage by oxygen radicals is accomplished through selenoproteins. ischemic stroke is associated with the generation of oxygen free radicals resulting in a condition of oxidative stress. supplementing stroke patients with antioxidant nutrients may improve survival.


Eligibility criteria:
inclusion criteria: 1. accepted ischemic stroke by brain ct or mri during last 72 h 2. ischemic stroke in middle cerebral artery territory 3. volume of stroke at list one third of mca territory 4. written informed consent. exclusion criteria: 1. known allergy to selenium 2. severe renal failure( cr clearance under 50 ml/min or serum cr upper than 2 3. severe hepatic failure( total bill upper than 2 or alt/ast 5 time upper than normal limit) 4. severe neurodegenerative disease such as severe dementia, alzheimer and parkinson 5. pregnancy or lactation
addition of lidocaine to levobupivacaine reduces intrathecal block duration

Conditions: Benign Prostate Hyperplasia

Summary: the main objective was to test the hypothesis that adding lidocaine to hyperbaric levobupivacaine could change the duration of levobupivacaine spinal block.

a satisfactory spinal anaesthesia requires both a fast onset and proper duration at the same time. transurethral resection of the prostate (tur-p) is a surgery of medium duration. the addition of lidocaine to hyperbaric bupivacaine shortens the duration of bupivacaine spinal block and therefore provides more rapid recovery. this property of lidocaine is not verified with other local anesthetics. levobupivacaine is a s-enantiomer of racemic bupivacaine and is a long acting local anesthetic.the aim of this prospective randomized controlled study was to investigate this effect of lidocaine, with a local anesthetic other than bupivacaine. it was hypothesized that the duration of the intrathecal block could change when performed with hyperbaric levobupivacaine mixed with low dose lidocaine and this technique could be consistent for the duration of tur-p surgery. participants will be followed on the day of surgery for primary and secondary outcome measures and 3 days postoperatively for complications (tns).

Eligibility criteria:
inclusion criteria: * elective transurethral resection of the prostate (tur-p) exclusion criteria: * patients with contraindications for spinal anesthesia, * known sensitivity to the study drugs, * emergency cases, and * patients who refused spinal anaesthesia were excluded

Keywords: hyperbaric levobupivacaine i̇ntrathecal lidocaine tur-p
sleep apnea and obesity affects on morphine pharmacokinetics

Conditions: Pediatric Sleep Apnea; Obesity; Morphine Metabolism

Summary: adenotonsillectomy (at) is one of the most common pediatric surgeries performed, and is estimated to comprise 530,000 procedures in children under 15 years of age. historically, the leading cause for these procedures was recurrent infections; however, more recently surgical indications include sleep disordered breathing and obstructive sleep apnea (osas). pre-operative polysomnography (psg) is recommended for all children with suspected osas prior to undergoing at, although it is unclear whether sleep disordered breathing characteristics predict post-operative outcomes or complications. obesity has become an epidemic in the pediatric population. more recently, an increased population of obese children are presenting for at with upper airway obstruction with or without tonsillar hypertrophy, which is similar to the adult etiology of osas. obesity is a multisystem disease, causing fatty liver and cardiac disease, defects in glucose metabolism, insulin resistance, leptin resistance, and creates a state of chronic inflammation. markers for inflammation, including tumor necrosis factor (tnf)-α, c-reactive protein (crp), leptin, interleukin (il)-6 and il-10, are abnormal in obese patients and have also been linked to more severe osas disease in children even after controlling for bmi. in pediatrics, medication dosing is based on an actual body-weight calculation, however, recent reports suggest that this dosing method is over-dosing patients with obesity. therefore, increased respiratory complications after surgery may be related to inappropriate intra-operative opioid dosing. specific aim 1 (sa1): to compare morphine pharmacokinetics in normal children \<=12 years of age, non-obese children with severe osas, and obese children with severe osas. the investigators hypothesize that obesity independently enhances morphine pharmacokinetics. specific aim 2 (sa2): to determine whether biomarkers related to obesity, chronic inflammation, and osas predict changes to morphine pharmacokinetics. the investigators hypothesize that inflammatory and obesity-related biomarkers are elevated in overweight children with osas, more so in obese children with osa, compared to lean children with osas. in addition, the investigators hypothesizes that leptin independently is linked to altered morphine pharmacokinetics.


Eligibility criteria:
inclusion criteria: * child presenting for surgery that will require opioids * age between 5 -12 years of age osas group: * pre-operative polysomnography study conducted prior to day of surgery obese: * body weight \>95th percentile for age. exclusion criteria: * emergency procedures involving at, including tonsillar bleeding * patients allergic to morphine * patients with comorbidities altering opioid metabolism (i.e. liver disease) * patients with chronic inflammatory, rheumatologic, or other confounding co-morbid diseases (i.e. crohns disease, ulcerative colitis, sickle cell, sjogren's, etc.)
controls for respiratory diseases

Conditions: Chronic Obstructive Pulmonary Disease; Asthma; Idiopathic Pulmonary Fibrosis; Nontuberculous Mycobacterium Infection; Bronchiectasis; Lung Cancer

Summary: this is the registry of control participants for patients with various respiratory diseases. we screened healthy volunteers who visited seoul national hospital healthcare system gangnam center for routine health check-up, and enrolled patients who agree to participate in the study. the participants undergo baseline questionnaires, provide blood specimen and information of the results of health check-up. we will include participants as controls if they have no significant respiratory symptom and no significant radiographic abnormality. the data from this registry will be compared with those from other registry of various respiratory diseases


Eligibility criteria:
inclusion criteria: * 19-90 years old male and female * underwent health check-up including chest radiography * obtained informed consent exclusion criteria: * those who showed a significant abnormal finding of chest radiography * those who reported a significant respiratory symptoms
open label trial studying the safety and effectiveness of iluvien® (190μg) in children and adolescents, who have recurrent non-infectious uveitis affecting the posterior segment of the eye.

Conditions: Non-infectious Uveitis Affecting the Posterior Segment of the Eye

Summary: the main aim is to test how safe and effective the medicine iluvien® (190μg) is for children and adolescents, who have non-infectious uveitis that keeps coming back and affects the back of the eye. the main thing alimera wants to find out is how well the implant works for treating non-infectious uveitis in the back of the eye. treatment success will be measured after 6 months of using the implant. the treatment will be considered successful if two things happen: 1. no swelling in the back of the eye called cystoid macular oedema; 2. a decrease in the cloudiness inside the eye, called vitreous haze, by at least two levels compared to how it was before the treatment, or the vitreous haze is completely gone. participants will: 1. receive a single treatment with iluvien®, which is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye for up to 36 months. 2. be followed for 36 months for checkups and tests


Eligibility criteria:
inclusion criteria: * males and females of ≥6 and \<18 years of age at time of consent * non-infectious posterior, intermediate or panuveitis in the study eye with a history of recurrence ≥1 per year as assessed by the investigator * uveitis in the study eye not adequately controlled by the preferred standard of care due to intolerable adverse effects or poor response, in the judgment of the investigator * treatment with systemic corticosteroid or other systemic therapies given for at least 3 months within the previous 12 months prior to day 1 exclusion criteria: * history of intraocular surgery in the study eye within 90 days of the screening visit. * hypersensitivity to fa or any component of iluvien® * history of any form of glaucoma or ocular hypertension in study eye, unless study eye has been previously treated with an incisional iop-lowering surgical procedure at least 90 days prior to the screening visit and that procedure has resulted in stable iop in the normal range (10-21 mmhg) * increased intraocular pressure \>25 mmhg or that required treatment including increases in medications, surgery (other than drainage surgery), or hospitalisations, within 4 weeks prior to baseline that, in the opinion of the investigator, would pose an unacceptable risk to the patient participating in the study
the effect of family history on insomnia during sobriety in alcoholics

Conditions: Insomnia

Summary: the investigators intend to assess the following: * the efficacy of cbti in treating insomnia during recovery, * does a family history of alcoholism moderate the insomnia symptoms, * does an improvement in insomnia lead to a decrease in impulsivity.

the primary goals of this pilot study are the following: a) to assess for the difference in improvement insomnia, after 8 weeks of treatment with recommended cbti, in veterans with alcohol dependence during early recovery, the secondary goals include the following: 1. to assess for any change in the alcohol consumption indices between the groups after 8 weeks of cbti, 2. to assess for change in psychiatric symptoms of mood and anxiety across the groups, 3. to assess for differences in insomnia in subjects, with and without a first degree family history of alcohol dependence, 4. to evaluate for any change in impulsivity-related measure with insomnia treatment.

Eligibility criteria:
inclusion criteria: 1. presence of insomnia currently 2. dsm iv diagnosis of alcohol dependence within the past year 3. not in acute alcohol withdrawal and within a year of sobriety from alcoholism 4. patients with moderate-severe sleep apnea compliant on their pap device 5. can speak, understand and print in english. 6. is capable of giving written informed consent. exclusion criteria: 1. dependence on psychoactive substance (excluding alcohol, nicotine and cannabis) in the past 12 months, or evidence of chronic opiate use. 2. unstable/serious psychiatric condition e.g. schizophrenia, bipolar disorder. 3. unstable or serious medical/neurologic illness 4. severe cognitive impairment 5. untreated moderate - severe obstructive sleep apnea
analgesic requirement for post-operative pain control in tlip interbody fusion

Conditions: Back Pain; Surgery-Complications; Narcotic Use; Physical Stress; Post Operative Pain

Summary: the goal of this clinical trail is to to compare the efficacy of thoracolumbar interfascial plane block with exparel vs with standard of care 0.25% bupivacaine hcl in patients undergoing 1-3 level elective transforaminal lumbar interbody fusion. the investigators hypothesize that thoracolumbar interfascial plane block with exparel will outperform standard of care (supplemented with interfascial plane block of 0.25% bupivacaine hcl) with regards to pain reduction, narcotic use, length of hospital stay, time to mobilization with physical therapy, narcotic usage in the hospital, and post operative pain scores.


Eligibility criteria:
inclusion criteria: * patients 18 years or older, * patients admitted to ahc for 1-3 level tlif, * patients who have given written informed consent, * bmi between 18-35 kg/m2, exclusion criteria: * patients with known allergic reactions to standard of care analgesics, * female patients who are pregnant * patients with any previous lumbar spine instrumented surgery, * chronic opioid use within 30 days prior to randomization that exceeds average ≥30 oral morphine equivalents/day, * patients with known allergy to local anesthetics, * patients with known or suspected to have neuromuscular disorders impairing neuromuscular blockade (e.g. myasthenia gravis).
cliavist in infectious and degenerative diseases of the spine

Conditions: Spine Infection

Summary: uspio contrast enhancement results from intracellular trapping of the iron particles in reactive cells, especially macrophages. 17fdg-pet studies have demonstrated that macrophages are present in spine infectious diseases but are absent in spine degenerative diseases. the aim of this work is to compare the enhancement induced by cliavist in both diseases. the absence of macrophages in degenerative lesions should help to differentiate them from infectious lesions, who should present contrast enhancement in relation to the presence of macrophages.


Eligibility criteria:
inclusion criteria: * spine infection or spine degenerative disease * patient agreement obtained exclusion criteria: * pregnancy * mri contra-indications * cliavist contra-indication * dextran allergy

Keywords: mri, cliavist, macrophage, infection, spine